• Orion’s Q3 2026 operating profit jumped 74% year over year to EUR 209.9 million.
• Net sales rose 28% to EUR 542.2 million; Nubeqa remained the main growth driver.
• First large-molecule asset ODM-216 advanced into clinical development.
• The 2026 outlook targets net sales of EUR 2.07–2.14 billion and operating profit of EUR 730–790 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.